Chamath Palihapitiya Said This To Eli Lilly's Gene Therapy That Slashes LDL Cholesterol Up To 62%

Chamath Palihapitiya reacted on X after Eli Lilly's VERVE-102 showed strong Phase 1b LDL cholesterol reduction results.

10 Health Care Stocks With Whale Alerts In Today's Session

Eli Lilly And Company Reports Phase 1b Data For VERVE-102 Gene-Editing Therapy, Dose-Dependent Lowering Of PCSK9 And LDL-C, With Both Reductions Sustained Over Follow-Up Of Up To 18 Months In

In the Phase 1b Heart-2 trial, a single intravenous infusion of VERVE-102 produced dose-dependent lowering of PCSK9 and LDL-C, with both reductions sustained over follow-up of up to 18 months in participants at high risk for cardiovascular disease

Eli Lilly Highlights Positive Late-Stage Foundayo Data At Obesity Conference

Eli Lilly shares gained after late-stage Foundayo data showed double-digit weight loss in adults aged 65 and older across obesity trials.

Dell Technologies Stock Hits 52-Week High - Here's Why

Dell hits a 52-week high as analysts boost price targets ahead of Q1 earnings, citing "parabolic" AI infrastructure demand.

Eli Lilly Announces Foundayo Shown To Significantly Reduce Body Weight In Phase 3 ATTAIN-1, ATTAIN-2 Studies

https://investor.lilly.com/news-releases/news-release-details/foundayo-orforglipron-once-daily-pill-taken-without-food-or

Eli Lilly's Triple Hormone Obesity Drug Shows Significant Weight Loss

Eli Lilly says retatrutide helped obesity trial participants lose up to 28.3% body weight in the Phase 3 TRIUMPH-1 study.

Lilly Announces Topline Results From TRIUMPH-1, A Phase 3 Clinical Trial Evaluating The Efficacy And Safety Of Retatrutide; At 80 Weeks, All Doses Met The Primary And Key Secondary Endpoints

Eli Lilly and Company (NYSE:LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating the efficacy and safety of

Just 10 Stocks Now Make Up Over Of S&P 500—Surpassing Dot-Com Bubble Levels

The 10 largest stocks now account for 41% of the S&P 500's market value, as investor money continues pouring.

Engage Bio Acquired by Lilly to Accelerate Development of Non-Viral Genetic Medicines; Under The Terms Of The Agreement, Eli Lilly Acquired Engage For Up To $202M In Cash

https://www.businesswire.com/news/home/20260520932076/en/Engage-Bio-Acquired-by-Lilly-to-Accelerate-Development-of-Non-Viral-Genetic-Medicines